← FDA DRUG APPROVALS

FDA NDA · NDA050754

AMOXIL

Sponsor: US ANTIBIOTICS

APPLICATION
NDA050754
TYPE
NDA
ORIGINAL APPROVAL
1998-07-10
LATEST ACTION
2024-05-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

AMOXIL · ReferenceDiscontinued
AMOXICILLIN 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
AMOXIL · ReferenceDiscontinued
AMOXICILLIN 875MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2024-05-01Labeling · Supplement 22 · standard — Label ↗AP
2022-11-02Labeling · Supplement 21 · standard — Letter ↗AP
2015-12-03Labeling · Supplement 20 · standard — Label ↗AP
2015-09-24Labeling · Supplement 19 · standard — Label ↗AP
2014-09-30Manufacturing (CMC) · Supplement 18 · standardAP
2011-11-16Labeling · Supplement 17 · unknown — Letter ↗AP
2011-11-16Labeling · Supplement 13 · standard — Label ↗AP
2011-11-16Labeling · Supplement 14 · standard — Letter ↗AP
2008-06-09Labeling · Supplement 11 · standard — Letter ↗AP
2008-03-28Labeling · Supplement 12 · standard — Label ↗AP
2006-01-26Labeling · Supplement 10 · standardAP
2004-07-13Labeling · Supplement 9 · standard — Letter ↗AP
2003-12-18Labeling · Supplement 8 · standard — Letter ↗AP
2003-05-12Labeling · Supplement 4 · standard — Letter ↗AP
2002-12-04Manufacturing (CMC) · Supplement 7 · standardAP
2002-05-01Manufacturing (CMC) · Supplement 6 · standardAP
2002-04-25Manufacturing (CMC) · Supplement 5 · standardAP
2002-04-10Labeling · Supplement 1 · standard — Review ↗AP
2001-04-17Manufacturing (CMC) · Supplement 3 · standardAP
2000-05-16Labeling · Supplement 2 · standard — Review ↗AP
1998-07-10Type 3 - New Dosage Form · Original · standard — Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →